Advanced Oncology Certified Nurse Practitioner (AOCNP) Certification Practice Test

Disable ads (and more) with a membership for a one time $2.99 payment

Master the Advanced Oncology Certified Nurse Practitioner exam. Use flashcards and multiple choice questions with hints and explanations to prepare for your certification success!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.


What is the least common cause of hypercalcemia associated with malignancies?

  1. Secretion of parathyroid hormone

  2. Secretion of vitamin D analogues by the tumor

  3. Bone metastases causing osteolysis

  4. Renal failure due to tumor lysis syndrome

The correct answer is: Secretion of vitamin D analogues by the tumor

The least common cause of hypercalcemia associated with malignancies is the secretion of vitamin D analogues by the tumor. While various malignancies can lead to hypercalcemia through several mechanisms, one of the most well-recognized is the paraneoplastic syndrome where tumors secrete substances that affect calcium metabolism. Generally, bone metastases are a prominent cause, as they lead to osteolysis, where bone tissue is broken down, releasing calcium into the bloodstream. Additionally, parathyroid hormone-related peptide (PTHrP) secretion mimics the action of parathyroid hormone, promoting calcium release from bones and increasing renal tubular reabsorption of calcium, making it a more common cause of hypercalcemia in malignancies. Secretion of vitamin D analogues by tumors, while a possible mechanism (especially in lymphoproliferative disorders), is relatively rare compared to these other mechanisms. Tumor lysis syndrome typically leads to renal failure due to a rapid release of intracellular contents, including phosphate, rather than causing hypercalcemia directly. Thus, this makes the secretion of vitamin D analogues the least common cause among the listed options.